Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

NCT02139592 · clinicaltrials.gov ↗
COMPLETED
Status
292
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda